KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$12.77 USD
-0.28 (-2.15%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $12.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KALV 12.77 -0.28(-2.15%)
Will KALV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KALV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALV
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KALV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV ...
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)
KalVista (KALV) Advances in Europe with Sebetralstat Approval
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista (KALV) Awaits EU Approval for Sebetralstat for Hereditary Angioedema | KALV Stock News